Case report: renal recovery in Goodpasture's syndrome treated with rituximab.
Anti-GBM disease
Goodpasture’s syndrome
Plasmapheresis
Rapidly progressive glomerulonephritis with pulmonary hemorrhage
Rituximab
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
24
12
2022
accepted:
07
01
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Successful induction of remission in anti-glomerular basement membrane (anti-GBM) glomerulonephritis can be obtained by using rituximab as a first-line immunosuppressive agent. We report the case of a 20-year-old male patient with Goodpasture's (anti-GBM) syndrome, with poor prognostic factors at presentation including intra-alveolar hemorrhage and dialysis-dependent rapidly progressive glomerulonephritis. The diagnosis was confirmed on kidney biopsy and serology (anti-GBM antibody titer). Rituximab was used as the first-line immunosuppressive agent in combination with pulse corticosteroids and plasmapheresis, to avoid potential side effects of cyclophosphamide. Anti-GBM antibody titers became undetectable after initiating rituximab. No adverse events were reported, and the patient became dialysis-independent after 6 months. This case reports the successful remission of a patient with Goodpasture's syndrome after induction with rituximab.
Identifiants
pubmed: 38427310
doi: 10.1007/s40620-024-01892-0
pii: 10.1007/s40620-024-01892-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to Italian Society of Nephrology.
Références
Levy J-B, Turner A-N, Rees A-J, Pusey C-D (2001) Long-term outcome of anti- glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134:1033–1042
doi: 10.7326/0003-4819-134-11-200106050-00009
pubmed: 11388816
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1–S276. https://doi.org/10.1016/j.kint.2021.05.021 . (PMID: 34556256)
doi: 10.1016/j.kint.2021.05.021
Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76(5):734–740. https://doi.org/10.1111/bcp.12098
doi: 10.1111/bcp.12098
pubmed: 23432476
pmcid: 3853532
Shiferaw B, Miro V, Smith C et al (2016) Goodpasture’s disease: an uncommon disease with an atypical clinical course. J Clin Med Res 8:52–55
doi: 10.14740/jocmr2379w
pubmed: 26668684
Cui Z, Zhao MH (2011) Advances in human antiglomerular basement membrane disease. Nat Rev Nephrol 7:697–705
doi: 10.1038/nrneph.2011.89
pubmed: 21769105
Lerner RA, Glassock RJ, Dixon FJ (1967) The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126:989–1004
doi: 10.1084/jem.126.6.989
pubmed: 4964566
pmcid: 2138413
McAdoo SP, Pusey CD (2017) Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 12:1162–1172
doi: 10.2215/CJN.01380217
pubmed: 28515156
pmcid: 5498345
Rivkees SA, Crawford JD (1988) The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259:2123–2125
doi: 10.1001/jama.1988.03720140043031
pubmed: 3162285
Watson AR, Rance CP, Bain J (1985) Long term effects of cyclophosphamide on testicular function. Br Med J (Clin Res Ed) 291(6507):1457–1460. https://doi.org/10.1136/bmj.291.6507.1457 . (PMID:3933709; PMCID:PMC1418091)
doi: 10.1136/bmj.291.6507.1457
pubmed: 3933709
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221e232
doi: 10.1056/NEJMoa0909905
Heitz M, Carron PL, Clavarino G, Jouve T, Pinel N, Guebre-Egziabher F, Rostaing L (2018) Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease. BMC Nephrol 19(1):241. https://doi.org/10.1186/s12882-018-1038-7 . (PMID:30236081; PMCID:PMC6149204)
doi: 10.1186/s12882-018-1038-7
pubmed: 30236081
pmcid: 6149204